Foreign companies demolished the "West" supplement "China" to invest in China and have intensified
Release time: 2010-08-12 & nbsp & nbsp & nbsp Source:
Recently，Merhado Hangzhou New Factory broke the soil; Previous，There are also many foreign companies to close some R & D centers and factories of some mature markets，Instead of investing in China。
Recently，Deputy Mayor of Hangzhou City, Pan Guili and Chairman and CEO of Merhado, Correa, signed the "Hangzhou Municipal Government and Merckon Cooperation Agreement" in Hangzhou。According to the newly signed agreement，Merckon announced its official breakthrough in China。The new plant is located in the Hangzhou Xiasha Economic and Technological Development Zone，Covering an area of 39,000 square meters，After completion, it will become one of the largest factories in pharmaceutical companies in the Asia -Pacific region。
Well -known，Although the global pharmaceutical market is still recovering，But multinational companies' investment in China is also getting bigger。According to Wang Jin, president of Manhattan Capital Management Consulting Company，Since this year，Many foreign companies choose to close some R & D centers and factories of mature markets，stake sports betting appstake online sports bettingThe purpose is to increase investment in emerging markets，Many foreign companies choose to build a new R & D center in China。
This year，Astrikan、GlaxoSmithk has closed overseas R & D centers and factories in succession，At the same time, increase investment in China。Current，In investment in the Chinese market，The construction of the R & D center becomes the first choice。But some people in the industry think，Although foreign -funded enterprises have been based in China R & D Center，But this does not mean that it can bring enough results。
Is it retreat?
Since 2009，multinational pharmaceutical companies began a new round of global industrial adjustment，Many pharmaceutical companies choose to close some R & D centers and factories。According to Dr. Wang Min, director of the Medical Department of Bayer Company，The new drug R & D project of pharmaceutical companies is closely related to economic development，The economic downturn in recent years，Pharmaceutical companies first take the cutting factory workers to relieve stress，The plan to reduce costs subsequent reducing costs will extend to the R & D department。
Contraction of multinational enterprises does not mean "retreat"，but it means the change of the direction of research and development。Many foreign companies' strategies are "retreating for enter"，With the disappearance of the old department，The new department and plan appeared again。
According to the reporter's understanding，Following the reduction of 25%of the disease research and development costs of Astrikang，Grammomsk Company announced，It has sold its research center in Italy to APTUIT，and plan to stop exploring research in the field of neuroscience such as pain and depression。
According to the reporter's understanding，This move is part of the Glangoscosk restructuring plan，It will save it $ 800 million，Use the main funds to the field with the highest return on investment。The company will transfer the focus to the field of neurodegenerative diseases My stake betting appand Stake Sports Bettingneurocyte inflammation，For this reason, a department that specializes in the development and commercialization of rare diseases。
For Merhado, which is in the forefront of the world，Also select the strategy of "retreat"，The development key will be specialized in emerging markets，Especially the Chinese market。
After the acquisition of Xianling Yaya Company，Merhadon plans to be in the next 2 years，Close 8 factories and 8 research centers globally。According to the reporter's understanding，This will save US $ 3.5 billion in expenses for Merhadon，and gradually turn the company's business focus to the field of patients and biopharmaceuticals，and transfer production capacity to other Merck Pharmaceutical Factory。
Expansion capacity
According to the reporter's understanding，Hangzhou Municipal Government will jointly promote the construction project of the new Chinese plant with Merck。According to the development forecast of Hangzhou Meroshadong，until 2012，The production capacity of the factory will reach saturation，and the current site requires greater development space，Therefore, the Hangzhou Economic and Technological Development Zone is also selected to build a new plant。
Kerry pointed out，Merhado and Hangzhou cooperate with new pharmaceuticals，Continuously expand the production scale in Hangzhou。Merhadon is ready to set up a foreign business enterprise in the development zone，Main pharmaceutical business; after the completion of the new factory project，A wholly -owned enterprise will be established，and will expand the investment scale in Hangzhou。
According to the reporter's understanding，Merhado's soothing drop is reduced after the price reduction，The effect of expansion is very obvious。According to its partners in the grassroots field ---- Related to the relevant person from the good doctor website，Merhadon's Shuzhi's sales in the grass -roots medical institutions increased a lot。Feng Naxi, president of Merck China, pointed out，In the future, I will try to further improve stake online sports bettingMy stake betting appthe distribution network，Let the product enter more community hospitals。So，Merhadon urgently needs to expand his production capacity。
Future，Merhadon Hangzhou New Factory will bear the packaging of all solid -stricken agent medicines and sterile products sold in the Chinese market。In addition，Hangzhou New Factory will also provide clinical research or commercial support for the listing and introduction of new products，and provide strategic development capabilities and innovative third -party logistics support。It is reported，Merck Hangzhou New Factory Project will be completed and put into operation in the first quarter of 2012，It is expected that the annual packaging output will exceed 300 million boxes。
The prospect is unpredictable
Although Merck's choosing price reduction is a novel market strategy，But for multinational companies，Cooperation and development through the establishment of a research and development center is always the first choice。
According to the personnel in China in China: "In the future, Merhado will also increase research and development investment in China。The world's first cancer vaccine developed by Merhado-Cervical Cancer Vaccine is also registered in China。”
Although Merhadon has not set up a R & D center in China，But Merhado also set up a southern brain gum tumor center with Guangzhou South Hospital，To develop this field of research and development。
Current，The research and development center of foreign companies mainly conduct cooperative research and development，That is, buying potential varieties in China。Current，Merhado is also actively carrying out business in this area。Merhado New Pharmaceutical Technical Product Cooperation and the introduction of Dr. Hu Jingshan, Director of Greater China，When the company cooperates with technology and products，Requires it to have a global patent、Unique competitiveness and larger market; when choosing a compound for cooperation，Requirement stake online sports bettingstake sports betting apptarget is a single molecule，and can be produced on a large scale。
Although the enthusiasm of foreign companies is high，But it may not be able to get the expected effect，According to an executive at a vice chairman of RDPAC，It is not realistic to buy varieties in China，If you have a good innovative compound，Research institutions are not willing to sell，I want to develop it by myself，It is not good to be able to sell it。
According to the reporter's understanding，Novartis's R & D Center has launched a 10 -year cooperation research and development in China，But the investment is not exchanged for the due income，At present, the center has not yet entered the new drug of Phase III clinical。
Recently，Deputy Mayor of Hangzhou City, Pan Guili and Chairman and CEO of Merhado, Correa, signed the "Hangzhou Municipal Government and Merckon Cooperation Agreement" in Hangzhou。According to the newly signed agreement，Merckon announced its official breakthrough in China。The new plant is located in the Hangzhou Xiasha Economic and Technological Development Zone，Covering an area of 39,000 square meters，After completion, it will become one of the largest factories in pharmaceutical companies in the Asia -Pacific region。
Well -known，Although the global pharmaceutical market is still recovering，But multinational companies' investment in China is also getting bigger。According to Wang Jin, president of Manhattan Capital Management Consulting Company，Since this year，Many foreign companies choose to close some R & D centers and factories of mature markets，stake sports betting appstake online sports bettingThe purpose is to increase investment in emerging markets，Many foreign companies choose to build a new R & D center in China。
This year，Astrikan、GlaxoSmithk has closed overseas R & D centers and factories in succession，At the same time, increase investment in China。Current，In investment in the Chinese market，The construction of the R & D center becomes the first choice。But some people in the industry think，Although foreign -funded enterprises have been based in China R & D Center，But this does not mean that it can bring enough results。
Is it retreat?
Since 2009，multinational pharmaceutical companies began a new round of global industrial adjustment，Many pharmaceutical companies choose to close some R & D centers and factories。According to Dr. Wang Min, director of the Medical Department of Bayer Company，The new drug R & D project of pharmaceutical companies is closely related to economic development，The economic downturn in recent years，Pharmaceutical companies first take the cutting factory workers to relieve stress，The plan to reduce costs subsequent reducing costs will extend to the R & D department。
Contraction of multinational enterprises does not mean "retreat"，but it means the change of the direction of research and development。Many foreign companies' strategies are "retreating for enter"，With the disappearance of the old department，The new department and plan appeared again。
According to the reporter's understanding，Following the reduction of 25%of the disease research and development costs of Astrikang，Grammomsk Company announced，It has sold its research center in Italy to APTUIT，and plan to stop exploring research in the field of neuroscience such as pain and depression。
According to the reporter's understanding，This move is part of the Glangoscosk restructuring plan，It will save it $ 800 million，Use the main funds to the field with the highest return on investment。The company will transfer the focus to the field of neurodegenerative diseases My stake betting appand Stake Sports Bettingneurocyte inflammation，For this reason, a department that specializes in the development and commercialization of rare diseases。
For Merhado, which is in the forefront of the world，Also select the strategy of "retreat"，The development key will be specialized in emerging markets，Especially the Chinese market。
After the acquisition of Xianling Yaya Company，Merhadon plans to be in the next 2 years，Close 8 factories and 8 research centers globally。According to the reporter's understanding，This will save US $ 3.5 billion in expenses for Merhadon，and gradually turn the company's business focus to the field of patients and biopharmaceuticals，and transfer production capacity to other Merck Pharmaceutical Factory。
Expansion capacity
According to the reporter's understanding，Hangzhou Municipal Government will jointly promote the construction project of the new Chinese plant with Merck。According to the development forecast of Hangzhou Meroshadong，until 2012，The production capacity of the factory will reach saturation，and the current site requires greater development space，Therefore, the Hangzhou Economic and Technological Development Zone is also selected to build a new plant。
Kerry pointed out，Merhado and Hangzhou cooperate with new pharmaceuticals，Continuously expand the production scale in Hangzhou。Merhadon is ready to set up a foreign business enterprise in the development zone，Main pharmaceutical business; after the completion of the new factory project，A wholly -owned enterprise will be established，and will expand the investment scale in Hangzhou。
According to the reporter's understanding，Merhado's soothing drop is reduced after the price reduction，The effect of expansion is very obvious。According to its partners in the grassroots field ---- Related to the relevant person from the good doctor website，Merhadon's Shuzhi's sales in the grass -roots medical institutions increased a lot。Feng Naxi, president of Merck China, pointed out，In the future, I will try to further improve stake online sports bettingMy stake betting appthe distribution network，Let the product enter more community hospitals。So，Merhadon urgently needs to expand his production capacity。
Future，Merhadon Hangzhou New Factory will bear the packaging of all solid -stricken agent medicines and sterile products sold in the Chinese market。In addition，Hangzhou New Factory will also provide clinical research or commercial support for the listing and introduction of new products，and provide strategic development capabilities and innovative third -party logistics support。It is reported，Merck Hangzhou New Factory Project will be completed and put into operation in the first quarter of 2012，It is expected that the annual packaging output will exceed 300 million boxes。
The prospect is unpredictable
Although Merck's choosing price reduction is a novel market strategy，But for multinational companies，Cooperation and development through the establishment of a research and development center is always the first choice。
According to the personnel in China in China: "In the future, Merhado will also increase research and development investment in China。The world's first cancer vaccine developed by Merhado-Cervical Cancer Vaccine is also registered in China。”
Although Merhadon has not set up a R & D center in China，But Merhado also set up a southern brain gum tumor center with Guangzhou South Hospital，To develop this field of research and development。
Current，The research and development center of foreign companies mainly conduct cooperative research and development，That is, buying potential varieties in China。Current，Merhado is also actively carrying out business in this area。Merhado New Pharmaceutical Technical Product Cooperation and the introduction of Dr. Hu Jingshan, Director of Greater China，When the company cooperates with technology and products，Requires it to have a global patent、Unique competitiveness and larger market; when choosing a compound for cooperation，Requirement stake online sports bettingstake sports betting apptarget is a single molecule，and can be produced on a large scale。
Although the enthusiasm of foreign companies is high，But it may not be able to get the expected effect，According to an executive at a vice chairman of RDPAC，It is not realistic to buy varieties in China，If you have a good innovative compound，Research institutions are not willing to sell，I want to develop it by myself，It is not good to be able to sell it。
According to the reporter's understanding，Novartis's R & D Center has launched a 10 -year cooperation research and development in China，But the investment is not exchanged for the due income，At present, the center has not yet entered the new drug of Phase III clinical。
